Statements (160)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:robot
gptkb:drug |
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Acel_Rx_Pharmaceuticals
|
| gptkbp:activities |
opioid receptor agonist
mu-opioid receptor agonist |
| gptkbp:advises |
follow prescribing information
monitor for side effects ensure proper dosing |
| gptkbp:application |
gptkb:public_transportation_system
surveillance delivery |
| gptkbp:battery_life |
8 hours
|
| gptkbp:class |
analgesics
opioids |
| gptkbp:clinical_trial |
gptkb:Europe
gptkb:United_States gptkb:Native_American_tribe gptkb:Alder_Bio_Pharmaceuticals gptkb:Research_Institute Phase 1 pharmaceutical companies Phase 2 Phase 3 private investors randomized controlled trial safety profile assessment double-blind study pain reduction placebo-controlled trial tolerability assessment |
| gptkbp:collaborations |
academic institutions
clinical research organizations |
| gptkbp:color |
gptkb:black
gptkb:white gray |
| gptkbp:communication |
gptkb:Wi-Fi
gptkb:Bluetooth |
| gptkbp:contraindication |
severe asthma
respiratory disorders alcohol use hypersensitivity to oxycodone concurrent use of MAO inhibitors |
| gptkbp:controls |
gptkb:military_officer
autonomous |
| gptkbp:deployment |
rural areas
urban areas industrial sites |
| gptkbp:designed_by |
ARX Corporation
|
| gptkbp:developed_by |
gptkb:Alder_Bio_Pharmaceuticals
|
| gptkbp:developer |
pharmaceutical companies
biotechnology firms |
| gptkbp:dosage_form |
spray
|
| gptkbp:effective_date |
not approved by FDA
|
| gptkbp:environment |
outdoor
indoor |
| gptkbp:features |
gptkb:robot
GPS navigation real-time data processing automated charging |
| gptkbp:formulation |
intranasal
nalbuphine hydrochloride |
| gptkbp:frequency |
as needed
|
| gptkbp:future_plans |
long-term effects
cost-effectiveness analysis patient-reported outcomes comparative efficacy studies |
| gptkbp:has_ability |
gptkb:hospital
obstacle avoidance |
| https://www.w3.org/2000/01/rdf-schema#label |
ARX-04
|
| gptkbp:indication |
chronic pain
acute pain post-operative pain pain from injury trauma-related pain |
| gptkbp:ingredients |
oxycodone
nalbuphine |
| gptkbp:invention |
patented
|
| gptkbp:investment |
acute pain management market
emergency medicine market post-operative pain market |
| gptkbp:is_designed_to |
acute pain relief
|
| gptkbp:is_effective_against |
under investigation
|
| gptkbp:is_used_for |
acute pain
severe pain management |
| gptkbp:maintenance |
6 months
|
| gptkbp:manager |
nasal
intranasal delivery |
| gptkbp:manufacturer |
gptkb:Alder_Bio_Pharmaceuticals
ARX Corporation |
| gptkbp:market |
gptkb:military_unit
commercial investigational not available in pharmacies |
| gptkbp:marketed_as |
gptkb:skincare_product
|
| gptkbp:max_speed |
60 km/h
|
| gptkbp:operating_system |
gptkb:operating_system
|
| gptkbp:origin |
gptkb:USA
|
| gptkbp:part_of |
robotics industry
ARX fleet autonomous systems market |
| gptkbp:population |
gptkb:Person
adults elderly post-operative patients cancer patients patients with neuropathic pain |
| gptkbp:price |
gptkb:$100,000
|
| gptkbp:project |
clinical development
|
| gptkbp:receives_funding_from |
gptkb:Company
non-profit organizations government grants private funding private investors pharmaceutical company funding |
| gptkbp:regulatory_compliance |
gptkb:standard
gptkb:FCC gptkb:CE_Marking not yet approved |
| gptkbp:research |
pharmacokinetics
efficacy studies safety studies enhanced patient satisfaction improved pain scores reduced opioid consumption |
| gptkbp:research_areas |
gptkb:healthcare_organization
gptkb:Duke_University gptkb:Johns_Hopkins_University gptkb:University_of_California gptkb:Cleveland_Clinic |
| gptkbp:research_focus |
pain management
opioid delivery systems |
| gptkbp:safety_features |
fire suppression
adverse event reporting under investigation collision detection emergency stop long-term follow-up |
| gptkbp:sensor |
gptkb:Photographer
LIDAR |
| gptkbp:side_effect |
dizziness
nausea constipation sedation respiratory depression |
| gptkbp:supports |
24/7 customer service
software updates technical training |
| gptkbp:target_audience |
patients with acute pain
patients with severe pain |
| gptkbp:targets |
mu-opioid receptor
kappa-opioid receptor |
| gptkbp:technology |
gptkb:API
gptkb:software_framework |
| gptkbp:type |
gptkb:engine
|
| gptkbp:user_interface |
gptkb:mobile_application
touchscreen voice control |
| gptkbp:weight |
1500 kg
|
| gptkbp:year_created |
gptkb:2021
|